Barinthus Biotherapeutics (BRNS) Assets Average (2021 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Assets Average came in at $95.2 million in Q1 2026, down 37.05% YoY from $151.2 million in Q1 2025, and down 8.23% on a QoQ basis from $103.7 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Assets Average (2021 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 6 years of Assets Average data on file, last reported at $95.2 million in Q1 2026.
- Quarterly Assets Average fell 37.05% year-over-year to $95.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.2 million (down 37.05% YoY) and the FY2025 annual result came in at $129.2 million, down 31.04% from the prior year.
- Assets Average slipped to $95.2 million in Q1 2026, from $103.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $285.6 million in Q2 2022 to a low of $95.2 million in Q1 2026.
- A 5-year average of $204.1 million and a median of $207.0 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average soared 161.03% — and 2025, when it slumped 40.58%.
- Tracing BRNS's Assets Average over 5 years: stood at $272.8 million in 2022, then decreased by 18.55% to $222.2 million in 2023, then retreated by 21.48% to $174.5 million in 2024, then plunged by 40.58% to $103.7 million in 2025, then slipped by 8.23% to $95.2 million in 2026.
- The last three Assets Average figures came in at $95.2 million (Q1 2026), $103.7 million (Q4 2025), and $119.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Barinthus Biotherapeutics | 25.01 Mn | 25.01 Mn | - | 87.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.02 Mn |
| Mar 31, 2026 | 95.16 Mn |
| Dec 31, 2025 | 103.69 Mn |
| Sep 30, 2025 | 119.38 Mn |
| Jun 30, 2025 | 135.78 Mn |
| Mar 31, 2025 | 151.16 Mn |
| Dec 31, 2024 | 174.51 Mn |
| Sep 30, 2024 | 187.72 Mn |
| Jun 30, 2024 | 193.12 Mn |
| Mar 31, 2024 | 206.99 Mn |
| Dec 31, 2023 | 222.24 Mn |
| Sep 30, 2023 | 238.05 Mn |
| Jun 30, 2023 | 253.97 Mn |
| Mar 31, 2023 | 266.01 Mn |
| Dec 31, 2022 | 272.84 Mn |
| Sep 30, 2022 | 280.27 Mn |
| Jun 30, 2022 | 285.59 Mn |
| Mar 31, 2022 | 283.42 Mn |
| Dec 31, 2021 | 268.64 Mn |
| Sep 30, 2021 | 258.20 Mn |